WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

C CARDIOVASCULAR SYSTEM

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.


C01 CARDIAC THERAPY

C01A CARDIAC GLYCOSIDES

This group comprises plain and combined preparations containing cardiac glycosides, incl. standardized herbal extracts. Cardiac glycosides in combination with substances in group C01D and C01E are classified in this group. Combinations with antihypertensives, beta blocking agents, calcium channel blockers and ACE inhibitors, see group C02, C07, C08 and C09 respectively.

The DDDs are based on the average maintenance dose for the treatment of cardiac failure. Exception: the DDD for deslanoside is for acute treatment.

C01B ANTIARRHYTHMICS, CLASS I AND III

This group comprises preparations used in the treatment of arrhythmias.
The agents are listed according to the Vaughan Williams classification of antiarrhythmics. The division of class I antiarrhythmics may vary, depending on the literature used. The 3rd ed. of Averys "Drug Treatment" (1987) and "Drugs" 31, 93 - 95, 1986 are used as a basis for the ATC classification. Class II antiarrhythmics see C07 and class IV, see C08 (e.g. verapamil).
Adenosine, which is also used as an antiarrhythmic, is classified in C01EB.
Combined preparations are classified at separate 5th levels using the corresponding 50-series. Combinations with psycholeptics are classified at separate 5th levels using the corresponding 70-series. Combinations with an antihypertensive e.g. reserpine are classified in C02AA.

The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias. The DDDs are based on the maintenance dose. Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.

C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

This group comprises agents used for various indications, e.g. hypotension. Respiratory stimulants are classified in R07AB.
Dihydroergotamine, which is used in the treatment of migraine as well as hypotension, is classified in N02CA - Ergot alkaloids.
Combinations with peripheral vasodilators, see C04 - Peripheral vasodilators.

This group includes various drugs used on different indications. The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).

C01D VASODILATORS USED IN CARDIAC DISEASES

This group comprises preparations used in ischemic heart diseases. See also C02 - Antihypertensives, C03 - Diuretics, C04 - Peripheral vasodilators, C07 - Beta blocking agents, C08 - Calcium channel blockers and C09 - Agents acting on the renin-angiotensin system.
Combinations with cardiac glycosides, see C01A.
Combinations with rauwolfia alkaloids, see C02AA.
Combinations with beta blocking agents, see C07.
Combinations with calcium channel blockers, see C08.

C01E OTHER CARDIAC PREPARATIONS

This group comprises various preparations used in the treatment of ischemic heart diseases, which cannot be classified in any of the preceding groups.

Last updated: 2024-01-26